The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available on the ...
Zacks.com on MSN4d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. As part of the ...
AMVUTTRA, whose generic name is Vutrisiran, received FDA approval in June 2022 for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...
Alnylam's Amvuttra followed these results with a once per quarter subcutaneous injection, which can be administered at home, with reductions of 28% and 33% for overall mortality and cardiovascular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback